Johnson & Johnson Invests $1 Billion in Next-Gen Cell Therapy Manufacturing in Pennsylvania
This is part of J&J's $55B investment in US manufacturing over the next few years.
Key findings
- Johnson & Johnson is investing more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania.
- The investment is part of Johnson & Johnson’s broader plan to invest $55 billion in the U.S. through early 2029.
Johnson & Johnson has announced a more than $1 billion investment to build a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The company says the site will expand its U.S. manufacturing capacity as it develops medicines across cancer, immune-mediated, and neurological diseases.
J&J is currently developing CAR-T therapies for oncology, and it acquired a company called Intra-Cellular Therapies in 2025, although it’s unclear if this acquisition is part of its cell therapy portfolio or not.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson. “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
Jobs and workforce development
The company expects the project to support more than 500 skilled biomanufacturing jobs when fully operational, along with more than 4,000 construction jobs during site development.
“Pennsylvania is a powerhouse for innovation and manufacturing in the life sciences,” said Governor Josh Shapiro. “Just a few years ago we weren’t even on the field – but today we’re competing and winning. We’ve done it by creating the first economic development plan for Pennsylvania in 2 decades, and following through on it by cutting red tape, making strategic investments in key industries like the life sciences, and strengthening our workforce. That’s why companies like Johnson & Johnson are choosing to double down on their investments here in our Commonwealth – because they know we’ve got the strategy, the workforce, and the speed they need to succeed.”
Pennsylvania footprint
Johnson & Johnson says its economic impact in Pennsylvania totals about $10 billion annually, citing an external economic analysis. The company reports that it has 10 facilities across the state totaling more than 2 million square feet, covering manufacturing, research, distribution, and office operations.
The announcement also ties into Johnson & Johnson’s previously announced plan to invest more than $55 billion in U.S. manufacturing, R&D, and technology through early 2029.
More information: jnj.com and innovativemedicine.jnj.com.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
